SEC Filings
PVH Names Frits van Paasschen, A Former Fortune 500 CEO, To Its Board
The Calvin Klein and Tommy Hilfiger owner calls the 65-year-old's appointment part of its ongoing board refreshment.
Product + growth @TheBullished. I build the software that writes the stories you read, and get them in front of as many people as possible.
SEC Filings
The Calvin Klein and Tommy Hilfiger owner calls the 65-year-old's appointment part of its ongoing board refreshment.
SEC Filings
Nassab moves to a $180,000-a-year advisory job through February 28, 2028, while the commercial unit's head takes over January 1.
SEC Filings
The Cleveland bank's Series U notes carry a fixed-to-floating rate and mature November 2, 2032.
SEC Filings
Block's board approved the restated bylaws on October 28, and they took effect immediately.
Earnings
Kary takes over December 18, and Dougherty stays on as an adviser through fiscal 2027 while Keysight keeps its fourth-quarter outlook.
SEC Filings
The sleep apnea implant maker took a $24.1 million restructuring charge, narrowed its 2026 revenue range and said it plans a return to growth in 2027.
SEC Filings
Apple posted $114.5 billion in revenue, up 12 percent, as research spending rose to $11.7 billion and tariff refunds lifted margins.
Deals
The chemical maker's third-quarter revenue reached $1,717 million, and its pending Olin merger is now expected to close in early 2027.
Earnings
Adjusted earnings of $4.34 a share topped guidance, while heavy equipment spending left free cash flow at negative $137.4 million.
Markets
The Huntington's gene therapy now has a May 1, 2027 FDA target date, but shares gave up an early gain at Monday's close.
SEC Filings
CRISPR Therapeutics holds $2,276.6 million in cash and won two FDA fast-track-style designations for its cholesterol-editing drug.
Deals
Record third-quarter revenue of $1,243.0 million met a $483.4 million net loss driven by acquired research expense.